What is he best known for?
The fields of study he is best known for:
Ludmil B. Alexandrov mostly deals with Genetics, Mutation, Cancer, Germline mutation and Genome.
His study in Kataegis, APOBEC, Somatic cell, Somatic evolution in cancer and DNA Mutational Analysis is carried out as part of his studies in Genetics.
Ludmil B. Alexandrov combines subjects such as Lineage, Exome and Point mutation with his study of Kataegis.
His Mutation research entails a greater understanding of Gene.
His work in Cancer is not limited to one particular discipline; it also encompasses Cancer research.
His research in Genome intersects with topics in Cancer development, Computational biology and Cancer genome.
His most cited work include:
- Signatures of mutational processes in human cancer (5372 citations)
- Mutational Processes Molding the Genomes of 21 Breast Cancers (1241 citations)
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences (1082 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Genetics, Mutation, Cancer, Cancer research and Genome.
His biological study spans a wide range of topics, including DNA damage and DNA repair.
His work on Carcinogenesis, Somatic evolution in cancer and Cancer cell as part of general Cancer study is frequently connected to Context, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
The concepts of his Cancer research study are interwoven with issues in Exome sequencing, Bioinformatics, Carcinoma, Metastasis and Leukemia.
His Genome research is multidisciplinary, incorporating perspectives in Computational biology and DNA sequencing.
His research integrates issues of MUTYH and Exome in his study of DNA Mutational Analysis.
He most often published in these fields:
- Genetics (54.37%)
- Mutation (43.12%)
- Cancer (37.50%)
What were the highlights of his more recent work (between 2019-2021)?
- Cancer (37.50%)
- Computational biology (17.50%)
- Genome (31.87%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Cancer, Computational biology, Genome, Cancer research and Mutation.
His Cancer research is multidisciplinary, relying on both Epigenomics, Gene mutation and Carcinoma, Papillary renal cell carcinomas.
His studies deal with areas such as Chromothripsis, Human cancer and Genomics as well as Computational biology.
Many of his research projects under Genome are closely connected to Radiological imaging with Radiological imaging, tying the diverse disciplines of science together.
His study in Cancer research is interdisciplinary in nature, drawing from both Stem cell, Cytokine and Hepatic stellate cell.
His study on Mutation is covered under Genetics.
Between 2019 and 2021, his most popular works were:
- Pan-cancer analysis of whole genomes (538 citations)
- The repertoire of mutational signatures in human cancer (454 citations)
- Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia (49 citations)
In his most recent research, the most cited papers focused on:
His primary areas of study are Mutation, Cancer research, Genome, DNA Mutational Analysis and Germline mutation.
His Mutation research incorporates elements of Immune checkpoint, Immunity, Immunology and Carcinogenesis.
His work carried out in the field of Genome brings together such families of science as Base sequence, Computational biology and Cancer genome.
The various areas that Ludmil B. Alexandrov examines in his DNA Mutational Analysis study include Cancer, Clone, MSH2 and Carcinogen.
His Carcinogen study necessitates a more in-depth grasp of Genetics.
Ludmil B. Alexandrov focuses mostly in the field of Germline mutation, narrowing it down to matters related to Germline and, in some cases, Whole genome sequencing, Point mutation, Genomics, Chromothripsis and Massive parallel sequencing.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
